Processa pharmaceuticals announces expansion of ngc-cap program into advanced or metastatic breast cancer

Fda and processa agree to expand ngc-cap development into breast cancer providing a more efficient path to approval fda agrees that existing data and studies can be used to support the phase 2 breast cancer trial design hanover, md, jan. 19, 2024 (globe newswire) -- processa pharmaceuticals, inc. (nasdaq: pcsa) (“processa” or the “company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it plans to expand the development of next generation capecitabine (“ngc-cap”) into the treatment of advanced or metastatic breast cancer beginning with its next phase 2 trial. following the processa meeting with the fda, processa has decided the next ngc-cap trial would be a phase 2 trial in breast cancer.
PCSA Ratings Summary
PCSA Quant Ranking